EP3461841A1 - Anticorps et dispositifs d'essai pour la détection de bactéries du genre campylobacter - Google Patents

Anticorps et dispositifs d'essai pour la détection de bactéries du genre campylobacter Download PDF

Info

Publication number
EP3461841A1
EP3461841A1 EP17382654.6A EP17382654A EP3461841A1 EP 3461841 A1 EP3461841 A1 EP 3461841A1 EP 17382654 A EP17382654 A EP 17382654A EP 3461841 A1 EP3461841 A1 EP 3461841A1
Authority
EP
European Patent Office
Prior art keywords
antibody
seq
test device
antibodies
dps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17382654.6A
Other languages
German (de)
English (en)
Other versions
EP3461841B1 (fr
Inventor
Oscar Landeta Elorz
Yolanda GARCÍA MIGUEL
Juan Enrique MARTÍNEZ OLIVÁN
Beatriz Velasco Michelena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Certest Biotec SL
Original Assignee
Certest Biotec SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP17382654.6A priority Critical patent/EP3461841B1/fr
Application filed by Certest Biotec SL filed Critical Certest Biotec SL
Priority to ES17382654T priority patent/ES2759622T3/es
Priority to JP2020520045A priority patent/JP7212682B2/ja
Priority to CN201880078136.0A priority patent/CN111727200B/zh
Priority to PCT/EP2018/076857 priority patent/WO2019068733A1/fr
Priority to US16/652,951 priority patent/US11312762B2/en
Priority to KR1020207011395A priority patent/KR102653734B1/ko
Publication of EP3461841A1 publication Critical patent/EP3461841A1/fr
Application granted granted Critical
Publication of EP3461841B1 publication Critical patent/EP3461841B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention can be included in the field of diagnostics. Specifically, the present invention provides an antibody which is specific for the DNA-Binding Protein from Starved Cells (Dps) of bacteria of the genus Campylobacter and a hybridoma which produces said antibody.
  • the antibody can be used in an immunochromatographic test device and in a method for detecting bacteria of the genus Campylobacter.
  • Campylobacter jejuni In humans, 85% to 95% of infections by the Campylobacter species involve Campylobacter jejuni, while Campylobacter coli is involved in a majority of the other cases. C. jejuni is one of the most common causes of food poisoning in the United States and in Europe. The vast majority of cases occur as isolated events, not as part of recognized outbreaks. Active surveillance through the Foodborne Diseases Active Surveillance Network (FoodNet) indicates that about 14 cases are diagnosed each year for each 100,000 persons in the population. The European Food Safety Authority estimated in 2011 that there are approximately nine million cases of human campylobacteriosis per year in the European Union.
  • FoodNet Foodborne Diseases Active Surveillance Network
  • test device which produces less false positives and which is more sensitive than the test devices currently available.
  • Dps DNA-Binding Protein from Starved Cells
  • Figure 1 Diagram of the immunochromatographic test device.
  • the test device comprises the following elements: an absorbent material (1), a support membrane (2) with a detection section (3) and a control section (4), a sample addition section (5) and a section of the device which comprises the labeled antibody (6).
  • the arrow indicates the flow direction.
  • the test device further comprises a plastic support (7).
  • the present invention provides an antibody which specifically binds Dps, a hybridoma which produces the antibody of the present invention and an immunochromatographic test device comprising: (a) a first antibody which specifically binds to Dps, (b) a second antibody which specifically binds to Dps, and (c) a support membrane, wherein the first antibody is immobilized on the support membrane and the second antibody is labeled.
  • the present invention provides a method for detecting bacteria of the genus Campylobacter in an isolated sample which comprises contacting the sample with the test device of the present invention, the use of the antibody of the present invention for the detection of bacteria of the genus Campylobacter and the use of the antibody of the present invention for the manufacture of an immunoassay test device.
  • the present invention provides an antibody which specifically binds Dps.
  • an antibody refers to a protein comprising at least one immunoglobulin variable domain sequence.
  • the term antibody includes, for example, full-length, mature antibodies and antigen-binding fragments of an antibody.
  • an antibody molecule can include a heavy (H) chain variable domain sequence (abbreviated herein as VH), and a light (L) chain variable domain sequence (abbreviated herein as VL).
  • an antibody in another example, includes two heavy (H) chain variable domain sequences and two light (L) chain variable domain sequence, thereby forming two antigen binding sites, such as Fab, Fab', F(ab')2, Fc, Fd, Fd', Fv, single chain antibodies (scFv for example), single variable domain antibodies, diabodies (Dab) (bivalent and bispecific), and chimeric (e.g., humanized) antibodies, which may be produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies. These functional antibody fragments retain the ability to selectively bind with their respective antigen or receptor.
  • Antibodies and antibody fragments can be from any class of antibodies including, but not limited to, IgG, IgA, IgM, IgD, and IgE, and from any subclass (e.g., IgG1, IgG2, IgG3, and IgG4) of antibodies.
  • the antibodies of the present invention can be monoclonal or polyclonal.
  • the antibody can also be a human, humanized, CDR-grafted, or in vitro generated antibody.
  • the antibody can have a heavy chain constant region chosen from, e.g., IgG1, IgG2, IgG3, or IgG4.
  • the antibody can also have a light chain chosen from, e.g., kappa or lambda.
  • antigen-binding fragments include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a diabody (dAb) fragment, which consists of a VH domain; (vi) a camelid or camelized variable domain; (vii) a single chain Fv (scFv), see e.g., Bird et al.
  • a Fab fragment a monovalent fragment consisting of the VL, VH, CL and CH1 domains
  • a F(ab')2 fragment a bivalent fragment comprising two Fab fragments linked by a
  • antibody includes intact molecules. Constant regions of the antibodies can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function or complement function).
  • Antibody molecules can also be single domain antibodies.
  • Single domain antibodies can include antibodies whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies.
  • Single domain antibodies may be any of the art, or any future single domain antibodies.
  • Single domain antibodies may be derived from any species including, but not limited to mouse, human, camel, llama, fish, shark, goat, rabbit, and bovine.
  • a single domain antibody is a naturally occurring single domain antibody known as heavy chain antibody devoid of light chains. Such single domain antibodies are disclosed in WO 9404678 , for example.
  • variable domain derived from a heavy chain antibody naturally devoid of light chain is known herein as a VHH or nanobody to distinguish it from the conventional VH of four chain immunoglobulins.
  • VHH molecule can be derived from antibodies raised in Camelidae species, for example in camel, llama, dromedary, alpaca and guanaco. Other species besides Camelidae may produce heavy chain antibodies naturally devoid of light chain; such VHHs are within the scope of the invention.
  • VH and VL regions can be subdivided into regions of hypervariability, termed “complementarity determining regions” (CDR), interspersed with regions that are more conserved, termed “framework regions” (FR or FW).
  • CDR complementarity determining regions
  • FR framework regions
  • CDR complementarity determining region
  • HCDR1, HCDR2, HCDR3 three CDRs in each heavy chain variable region
  • LCDR1, LCDR2, LCDR3 three CDRs in each light chain variable region
  • monoclonal antibody refers to a preparation of antibody molecules of single molecular composition.
  • a monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.
  • a monoclonal antibody can be made by hybridoma technology or by methods that do not use hybridoma technology (e.g., recombinant methods).
  • the antibody thereof can be a polyclonal or a monoclonal antibody.
  • the antibody can be recombinantly produced, e.g., produced by phage display or by combinatorial methods.
  • the antibody is a monoclonal antibody.
  • Phage display and combinatorial methods for generating antibodies are known in the art (as described in, e.g., Ladner et al. U.S. Patent No.5,223,409 ; Kang et al. International Publication No. WO 92/18619 ; Dower et al. International Publication No. WO 91/17271 ; Winter et al. International Publication WO 92/20791 ; Markland et al. International Publication No. WO 92/15679 ; Breitling et al. International Publication WO 93/01288 ; McCafferty et al. International Publication No. WO 92/01047 ; Garrard et al. International Publication No.
  • WO 92/09690 Ladner et al. International Publication No. WO 90/02809 ; Fuchs et al. (1991) Bio/Technology 9:1370-1372 ; Hay et al. (1992) Hum Antibod Hybridomas 3:81-85 ; Huse et al. (1989) Science 246:1275-1281 ; Griffths et al. (1993) EMBO J 12:725-734 ; Hawkins et al. (1992) J Mol Biol 226:889-896 ; Clackson et al. (1991) Nature 352:624-628 ; Gram et al.
  • the antibody is a fully human antibody (e.g., an antibody made in a mouse which has been genetically engineered to produce an antibody from a human immunoglobulin sequence), or a non-human antibody, e.g., a rodent (mouse or rat), goat, primate (e.g., monkey), camel antibody.
  • a rodent mouse or rat
  • the non-human antibody is a rodent (mouse or rat antibody).
  • Methods of producing rodent antibodies are known in the art.
  • Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al. International Application WO 91/00906 , Kucherlapati et al. PCT publication WO 91/10741 ; Lonberg et al. International Application WO 92/03918 ; Kay et al. International Application 92/03917 ; Lonberg, N. et al.1994 Nature 368:856-859 ; Green, L.L.
  • An antibody can be one in which the variable region, or a portion thereof, e.g., the CDRs, are generated in a non-human organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and humanized antibodies are within the invention. Antibodies generated in a non-human organism, e.g., a rat or mouse, and then modified, e.g., in the variable framework or constant region, to decrease antigenicity in a human are within the invention.
  • Chimeric antibodies can be produced by recombinant DNA techniques known in the art (see Robinson et al., International Patent Publication PCT/US86/02269 ; Akira, et al., European Patent Application 184,187 ; Taniguchi, M., European Patent Application 171,496 ; Morrison et al., European Patent Application 173,494 ; Neuberger et al., International Application WO 86/01533 ; Cabilly et al. U.S. Patent No.4,816,567 ; Cabilly et al., European Patent Application 125,023 ; Better et al. (1988 Science 240:1041-1043 ); Liu et al.
  • a humanized or CDR-grafted antibody will have at least one or two but generally all three recipient CDRs (of heavy and or light immuoglobulin chains) replaced with a donor CDR.
  • the antibody may be replaced with at least a portion of a non-human CDR or only some of the CDRs may be replaced with non-human CDRs. It is only necessary to replace the number of CDRs required for binding of the humanized antibody to Dsp.
  • the donor will be a rodent antibody, e.g., a rat or mouse antibody
  • the recipient will be a human framework or a human consensus framework.
  • the immunoglobulin providing the CDRs is called the "donor” and the immunoglobulin providing the framework is called the "acceptor".
  • the donor immunoglobulin is a non-human (e.g., rodent) immunoglobulin.
  • the acceptor framework is a naturally-occurring (e.g., a human) framework or a consensus framework, or a sequence about 85% or higher, preferably 90%, 95%, 99% or higher identical thereto.
  • the term "consensus sequence” refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (see e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987 )). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence.
  • a “consensus framework” refers to the framework region in the consensus immunoglobulin sequence.
  • An antibody can be humanized by methods known in the art (see e.g., Morrison, S. L., 1985, Science 229:1202-1207 , by Oi et al., 1986, BioTechniques 4:214 , and by Queen et al. US 5,585,089 , US 5,693,761 and US 5,693,762 , the contents of all of which are hereby incorporated by reference).
  • Humanized or CDR-grafted antibodies can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDRs of an immunoglobulin chain can be replaced. See e.g., U.S. Patent 5,225,539 ; Jones et al.1986 Nature 321:552-525 ; Verhoeyan et al.1988 Science 239:1534 ; Beidler et al.1988 J. Immunol.141:4053-4060 ; Winter US 5,225,539 , the contents of all of which are hereby expressly incorporated by reference.
  • humanized antibodies in which specific amino acids have been substituted, deleted or added. Criteria for selecting amino acids from the donor are described in US 5,585,089 , e.g., columns 12-16 of US 5,585,089 , e.g., columns 12-16 of US 5,585,089 , the contents of which are hereby incorporated by reference. Other techniques for humanizing antibodies are described in Padlan et al. EP 519596 A1, published on December 23, 1992 .
  • the antibody can be a single chain antibody.
  • a single-chain antibody (scFV) may be engineered (see, for example, Colcher, D. et al. (1999) Ann N Y Acad Sci 880:263-80 ; and Reiter, Y. (1996) Clin Cancer Res 2:245-52 ).
  • the single chain antibody can be dimerized or multimerized to generate multivalent antibodies having specificities for different epitopes of the same target protein.
  • the antibody has a heavy chain constant region chosen from, e.g., the heavy chain constant regions of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE; particularly, chosen from, e.g., the (e.g., human) heavy chain constant regions of IgG1, IgG2, IgG3, and IgG4.
  • the antibody has a light chain constant region chosen from, e.g., the (e.g., human) light chain constant regions of kappa or lambda.
  • the constant region can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, and/or complement function).
  • the antibody has effector function and can fix complement. In other embodiments the antibody does not recruit effector cells or fix complement.
  • the antibody has reduced or no ability to bind an Fc receptor. For example, it is a isotype or subtype, fragment or other mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.
  • Antibodies with altered function e.g. altered affinity for an effector ligand, such as FcR on a cell, or the C1 component of complement can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see e.g., EP 388,151 A1 , U.S. Pat. No. 5,624,821 and U.S. Pat. No.5,648,260 , the contents of all of which are hereby incorporated by reference). Similar type of alterations could be described which if applied to the murine, or other species immunoglobulin would reduce or eliminate these functions.
  • an antibody can be derivatized or linked to another functional molecule (e.g., another peptide or protein).
  • a "derivatized" antibody molecule is one that has been modified. Methods of derivatization include but are not limited to the addition of a fluorescent moiety, a radionucleotide, a toxin, an enzyme or an affinity ligand such as biotin. Accordingly, the antibody molecules of the invention are intended to include derivatized and otherwise modified forms of the antibodies described herein, including immunoadhesion molecules.
  • an antibody molecule can be functionally linked (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate association of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).
  • another antibody e.g., a bispecific antibody or a diabody
  • detectable agent e.g., a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate association of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).
  • One type of derivatized antibody molecule is produced by crosslinking two or more antibodies (of the same type or of different types, e.g., to create bispecific antibodies).
  • Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional (e.g., disuccinimidyl suberate).
  • Such linkers are available from Pierce Chemical Company, Rockford, III.
  • Radioactive isotopes can be used in diagnostic or therapeutic applications.
  • radioactive isotopes include, but are not limited to iodine (1311 or 1251), yttrium (90Y), lutetium (177Lu), actinium (225Ac), praseodymium, astatine (211At), rhenium (186Re), bismuth (212Bi or 213Bi), indium (111 In), technetium (99 mTc), phosphorus (32P), rhodium (188Rh), sulfur (35S), carbon (14C), tritium (3H), chromium (51Cr), chlorine (36CI), cobalt (57Co or 58Co), iron (59Fe), selenium (75Se), or gallium (67Ga).
  • Radioisotopes useful as labels include iodine (1311 or 1251), indium (111In), technetium (99mTc), phosphorus (32P), carbon (14C), and tritium (3 H), or one or more of the therapeutic isotopes listed above.
  • the invention provides radiolabeled antibody molecules and methods of labeling the same.
  • a method of labeling an antibody molecule is disclosed. The method includes contacting an antibody molecule, with a chelating agent, to thereby produce a conjugated antibody.
  • the conjugated antibody is radiolabeled with a radioisotope, e.g., 111Indium, 90Yttrium and 177Lutetium, to thereby produce a labeled antibody molecule.
  • Dps or "DNA-Binding Protein from Starved Cells” refers to a protein from the ferritin superfamily which may be characterized by the entries under the accession number Q0P891 ( C. jejuni ) and/or A0A0Q2JBU3 (C. coli ) in the UniProtKB database. Dps preferably refers to the Dps of C. jejuni and/or the Dps of C. coli.
  • the antibody does not produce any signal in a sandwich immunoassay in the absence of Dps and/or the antibody can detect less than 3 ng/ml of Dps when used in a sandwich immunoassay.
  • the sandwich immunoassay is an immunochromatographic assay. More preferably, the two antibodies used in the sandwich immunoassay are the antibody of the present invention.
  • CL30Camp in combination with CL30Camp produces no background noise when a sample comprising PBS + 0.1 % BSA is applied to the immunochromatographic test device.
  • Tables 2 and 3 of the Examples the immunochromatographic test device is shown to detect less than 3 ng/ml of Dps from C. jejuni and C . coli.
  • the antibody can detect less than 3 ng/ml of Dps when used in a sandwich immunoassay, preferably an immunochromatographic assay.
  • the antibody can detect less than 2 or 1.5 ng/ml of Dps. More preferably, the antibody can detect less than 1 ng/ml of Dps.
  • the antibody is obtained or obtainable by immunizing an animal with native or recombinant Dps. In an alternative embodiment, the antibody is obtained or obtainable by immunizing an animal with an immunogen that comprises SEQ ID NO: 11 and/or SEQ ID NO: 12. In a preferred embodiment, the antibody specifically binds to SEQ ID NO: 11 and/or SEQ ID NO: 12.
  • SEQ ID NO: 11 is the Dps of C. jejuni and has the following sequence:
  • SEQ ID NO: 12 is the Dps of C. coli and has the following sequence:
  • the antibody comprises a light chain variable region (VL) and a heavy chain variable region (VH), wherein said VL comprises LCDR1, LCDR2 and LCDR3 polypeptides and VH comprises HCDR1, HCDR2 and HCDR3 polypeptides, wherein LCDR1 is SASSSVSSSYLH (SEQ ID NO: 1), LCDR2 is RTSNLAS (SEQ ID NO: 2), LCDR3 is QQWSGYPFT (SEQ ID NO: 3), HCDR1 is GFSLTSSGVH (SEQ ID NO: 4), HCDR2 is VIWRGGSTDYNAAFMS (SEQ ID NO: 5) and HCDR3 is NYYYGTSPDYFDY (SEQ ID NO: 6).
  • VL light chain variable region
  • VH heavy chain variable region
  • said VL comprises LCDR1, LCDR2 and LCDR3 polypeptides
  • VH comprises HCDR1, HCDR2 and HCDR3 polypeptides
  • LCDR1 is SASSSVSSSYL
  • SEQ ID NO: 7 is the VL fragment present in CL30Camp and has the following sequence:
  • SEQ ID NO: 8 is the VH fragment present in CL30Camp and has the following sequence:
  • the antibody comprises a VL and a VH, wherein the VL is SEQ ID NO: 7 and the VH is SEQ ID NO: 8.
  • SEQ ID NO: 9 is the LC present in CL30Camp and has the following sequence:
  • SEQ ID NO: 10 is the HC present in CL30Camp and has the following sequence:
  • the antibody comprises a light chain (LC) and a heavy chain (HC), and the LC is SEQ ID NO: 9 and the HC is SEQ ID NO: 10.
  • the antibody comprises two LCs and two HCs, wherein the LCs are SEQ ID NO: 9 and the HCs are SEQ ID NO: 10.
  • the antibody is a monoclonal antibody.
  • the anti-Dps antibody may be labeled. Labeling may be performed by using any ordinary method.
  • the labeling substance used for labeling is preferably an insoluble particle.
  • suitable particles include: colored synthetic polymer particles obtained by dye-molecule labeling synthetic polymers such as latex, polyethylene, polypropylene, polystyrene, a styrenebutadiene copolymer, polyvinyl chloride, polyvinyl acetate, polyacrylamide, polymethacrylate, a styrene-methacrylate copolymer, polyglycidyl methacrylate, and an acrolein-ethylene glycol dimethacrylate copolymer; colloidal metal particles (gold, silver, copper, iron, platinum, palladium, and a mixture thereof (for example, a mixture of gold and platinum, a mixture of gold and silver, and a mixture of palladium and platinum)); and red blood cells.
  • the particle allows a change to be easily and quickly checked by visual inspection.
  • Colored synthetic polymer particles or colloidal metal particles may be used for this purpose.
  • the particles have a particle size of, for example, 15 to 400 nm, preferably 100 to 400 nm for colored synthetic polymer particles or 30 to 80 nm for colloidal metal particles.
  • the colloidal metal particles may be commercially available products, or may be prepared by using an ordinary method.
  • 0.1 to 100 mg, preferably 0.5 to 20 mg of anti-Dps antibody is typically added to 1 L of a colloidal metal particle solution (typically, an absorbance of about 2.0 at 540 nm), and the mixture is refrigerated, or stirred at room temperature for 5 minutes to 24 hours. After blocking with bovine serum albumin (BSA; typically 0.01 to 10 g, preferably 0.1 to 2 g), the solution is centrifuged, and the resulting precipitate is obtained as anti-Dps antibodies labeled with the colloidal metal particles.
  • BSA bovine serum albumin
  • the antibody is labeled with a colored synthetic polymer particle and/or a colloidal metal particle.
  • the colored synthetic polymer particle comprises polystyrene.
  • the present invention provides an immunochromatographic test device comprising: (a) a first antibody which specifically binds to Dps, (b) a second antibody which specifically binds to Dps, and (c) a support membrane, wherein the first antibody is immobilized on the support membrane and the second antibody is labeled.
  • the term “immobilize” refers to attaching an antibody on a support such as a membrane so that the antibody can no longer move from its position on the support.
  • the first antibody is a capture antibody, and constitutes a detection section by being immobilized on the support.
  • detection section refers to a site where the presence of an antigen is detected by capturing the sample antigen which is attached to or attaches to the second antibody.
  • the support membrane may be of any material which allows the first antibody to be immobilized through electrostatic interactions, hydrophobic interactions or chemical coupling and on which substances such as the sample and the second antibody can move to the detection site.
  • suitable support membranes include nitrocellulose, polyvinylidene difluoride (PVDF), and cellulose acetate.
  • the support membrane comprises a control section for checking whether the sample has developed properly.
  • a substance that can to bind to a control substance is immobilized on the control section.
  • the locations of the detection section and the control section on the support are not particularly limited.
  • the control section is downstream of the detection section.
  • test device of the present invention a liquid sample dropped onto the sample addition section of the device wicks towards a section of the device which comprises the second antibody, and the mixture of the sample and the labeled antibody migrate through the support membrane, and the signal develops at the detection site (see Figure 1A ).
  • the antigen and the labeled antibody form an immunocomplex when the sample contains Dps.
  • the first antibody captures the complex through an antigen-antibody interaction, and the conjugate accumulates and develops color. The presence or absence of antigen in the sample can then be determined by visually checking the extent of the color at the detection section.
  • the test device may further comprise a control labeled substance in or adjacent to the section of the device which comprises the second antibody.
  • the control labeled substance can be captured by a substance that can bind the control labeled substance at the control section, and the control labeled substance accumulates and develops color.
  • the second antibody is also used as a control labeled substance, the residual second antibody that did not form a complex with the antigen in the sample passes through the detection site, and is captured by a substance that is immobilized at the downstream control section. The labeled antibody accumulates and develops color.
  • the first antibody is the antibody of the present invention, i.e. any one of the antibody embodiments disclosed previously.
  • the second antibody is the antibody of the present invention.
  • both the first and the second antibody are the antibody of the present invention.
  • the first and second antibody comprise a light chain variable region (VL) and a heavy chain variable region (VH), wherein said VL comprises LCDR1, LCDR2 and LCDR3 polypeptides and VH comprises HCDR1, HCDR2 and HCDR3 polypeptides, wherein LCDR1 is SASSSVSSSYLH (SEQ ID NO: 1), LCDR2 is RTSNLAS (SEQ ID NO: 2), LCDR3 is QQWSGYPFT (SEQ ID NO: 3), HCDR1 is GFSLTSSGVH (SEQ ID NO: 4), HCDR2 is VIWRGGSTDYNAAFMS (SEQ ID NO: 5) and HCDR3 is NYYYGTSPDYFDY (SEQ ID NO: 6).
  • VL light chain variable region
  • VH heavy chain variable region
  • said VL comprises LCDR1, LCDR2 and LCDR3 polypeptides
  • VH comprises HCDR1, HCDR2 and HCDR3 polypeptides
  • LCDR1 is SASSSVS
  • the first and second antibody comprise a VL and a VH, wherein the VL is SEQ ID NO: 7 and the VH is SEQ ID NO: 8.
  • the first and second antibody comprise a LC and a HC, wherein the LC is SEQ ID NO: 9 and the HC is SEQ ID NO: 10.
  • the second antibody is labeled, preferably with a colored synthetic polymer particle and/or a colloidal metal particle. More preferably, the second antibody is labeled with a colored synthetic polymer particle.
  • the present invention provides a method for detecting bacteria of the genus Campylobacter in an isolated sample which comprises contacting the sample with the test device of the present invention.
  • the bacteria of the genus Campylobacter is of the species Campylobacter jejuni and/or Campylobacter coli.
  • the isolated sample is an isolated stool sample.
  • the stool sample may be prepared by dispersing a stool sample in a pH 8.4 Tris-base buffer before contacting the sample with the test device of the present invention.
  • the present invention provides the use of the antibody of the present invention for the detection of bacteria of the genus Campylobacter.
  • the bacteria of the genus Campylobacter is of the species Campylobacter jejuni and/or Campylobacter coli.
  • the antibody of the present invention is used to detect bacteria of the genus Campylobacter in a stool sample.
  • the bacteria of the genus Campylobacter is of the species Campylobacter jejuni and/or Campylobacter coli.
  • the preset application provides the use of the antibody of the present invention for the manufacture of an immunoassay test device.
  • the term "immunoassay test device" can refer to any test device which comprises at least one antibody. Examples of test devices include immunochromatographic test devices, ELISA test devices, and immunoprecipitation test devices.
  • the immunoassay test device may then be used in a method for detecting bacteria of the genus Campylobacter in an isolated sample which comprises contacting the sample with the immunoassay test device.
  • the bacteria of the genus Campylobacter is of the species Campylobacter jejuni and/or Campylobacter coli. More preferably, the bacteria of the genus Campylobacter is of the species Campylobacter jejuni and/or Campylobacter coli and the isolated sample is an isolated stool sample.
  • the antibody of the present invention is used to manufacture the immunochromatographic test device of the present invention.
  • the present invention provides a hybridoma which produces the antibody of the present invention.
  • Monoclonal antibodies can be generated by immunizing mice with a Dps-derived antigen. Splenocytes from these mice immunized with the antigen of interest are used to produce hybridomas that secrete mAbs with specific affinities for epitopes (see, e.g., Wood et al. International Application WO 91/00906 , Kucherlapati et al. PCT publication WO 91/10741 ; Lonberg et al. International Application WO 92/03918 ; Kay et al. International Application 92/03917 ; Lonberg, N. et al.1994 Nature 368:856-859 ; Green, L.L. et al.1994 Nature Genet.
  • the CL30Camp monoclonal antibody was obtained from the hybridoma of the same name. Briefly, a hybridoma which produces the monoclonal antibody CL30Camp was obtained by performing standard protocols known in the art ( KOHLER G Milstein C Continuous cultures of fused cells secreting antibody of predefined specificity Nature 1975 Aug 7 0028-0836 256 5517 495-497 ).
  • mice BALB / c type mice were immunized with purified, native Dps (the purified, native Dps was obtained through the methods described in Ishikawa et al., 2003. J. Bacteriol. 185(3): 1010-1017 ). Lymphocytes from immunized mice were fused with a myeloma cell line, specifically a SP20 cell line, and the hybridomas that were obtained were screened by ELISA to find clones which produce antibodies that bind to Dps. To perform the ELISA, wells of a 96 well microtiter plate were coated with a rabbit polyclonal anti-Dps antibody in 100 mM carbonate buffer pH 9 at 37 °C for 2 h.
  • the wells were washed and then a Dps solution in PBS containing 1 % (w/v) BSA (bovine serum albumin) was added.
  • BSA bovine serum albumin
  • the wells were washed again and then the supernatant of a hybridoma cell line culture was added to each well.
  • the presence of antibody which can bind to the Dps was revealed using an anti-mouse IgG peroxidase conjugate (Sigma-Aldrich) and the corresponding substrate.
  • hybridomas which secreted antibodies with high specificity and affinity for Dps were selected.
  • the ones that produced good titers of antibody which performed favorably in thermal stress tests were further selected.
  • the antibodies were purified using Protein A affinity chromatography using methods which are common in the art (see the " Affinity Chromatography Vol. 1: Antibodies” handbook 18103746 AF published on 04/2017 by GE Healthcare Bio-Sciences AB ).
  • CL30Camp was selected because it had high specificity and sensitivity in ELISA tests as well as in immunochromatography tests (Table 1, the sample used was PBS containing 0.1% (w/v) BSA).
  • Anti-Dps antibodies were labeled with colored polystyrene nanoparticles (K1 020 Estapor®, Merck, Darmstadt, Germany).
  • the colored nanoparticles comprised carboxyl groups on the surface and had an average diameter of around 300 nm.
  • the antibodies were labeled as follows: a 1 mL solution containing 10% (w/v) particles was washed, centrifuged and resuspended in a 10 mM MES (2- (N-morpholino) ethanesulfonic acid) buffer with a pH of 6.0. EDC (1-ethyl-3- (3-dimethylaminopropyl) carbodiimide) was then added to a final concentration of 5 mM. The solution was incubated for 1 hour at 37 °C and then excess reagent was removed by centrifuging the solution and removing the supernatant.
  • the activated particles were resuspended in 10 mM MES pH 6 and the antibody was added to a surface concentration of 2 mg/m 2 .
  • the solution was then incubated for 4 hours at 25 °C and the labeled antibodies were then washed with a solution containing 0.1% (w/v) Tween-20.
  • the labeled antibodies were diluted in a 0.05% (w/v) Tris (tris (hydroxymethyl) aminomethane) pH 8.0 buffer solution containing 10% (w/v) sucrose, 2% (w/v) BSA, 1% (w/v) PEG-6000 and 2% (w/v) Tween-20.
  • This solution was deposited at a rate of 15 ⁇ l/cm on woven polyester fibers with a width of 29 mm.
  • the polyester fibers were dried for 24 hours in a chamber at 30 °C and 20% relative humidity.
  • a PBS buffer containing 1 mg/mL of anti-Dps antibody was deposited in a linear fashion on a nitrocellulose membrane which had a laminated width of 25 mm and a pore size of between 10 and 30 microns.
  • the antibody solution was deposited at a rate of 1 ⁇ L/cm.
  • the membrane was then dried for 24 hours in a chamber at 30 ° C and 20% relative humidity.
  • Polyclonal rabbit anti-mouse IgG was deposited on the control section in parallel to the deposit of the anti-Dps antibody on the detection section. The same conditions were used for the deposit of the Polyclonal rabbit anti-mouse IgG on the nitrocellulose membrane.
  • conjugate material sample addition section and section which comprises the labeled antibody
  • support membrane and the absorbent material was assembled as indicated in Figure 1B and 1C on a plastic support with an adhesive foil. The strips were transversely cut to a width of 4 mm.
  • the solution used for dispersing stool samples consisted of an aqueous solution of 200 mM Tris buffer with a pH of 8.4. This dispersion solution was dispensed in vials for sampling. Each vial contained 1 mL of solution.
  • Example 5 Limit of detection of the test device for Dps of C. jejuni and C. coli
EP17382654.6A 2017-10-02 2017-10-02 Anticorps contre dps et dispositifs d'essai pour la détection de bactéries du genre campylobacter Active EP3461841B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES17382654T ES2759622T3 (es) 2017-10-02 2017-10-02 Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
EP17382654.6A EP3461841B1 (fr) 2017-10-02 2017-10-02 Anticorps contre dps et dispositifs d'essai pour la détection de bactéries du genre campylobacter
CN201880078136.0A CN111727200B (zh) 2017-10-02 2018-10-02 用于检测弯曲杆菌属细菌的抗体和测试设备
PCT/EP2018/076857 WO2019068733A1 (fr) 2017-10-02 2018-10-02 Anticorps et dispositifs de test pour la détection de bactéries du genre campylobacter
JP2020520045A JP7212682B2 (ja) 2017-10-02 2018-10-02 カンピロバクター属の細菌の検出のための抗体および試験デバイス
US16/652,951 US11312762B2 (en) 2017-10-02 2018-10-02 Antibodies and test devices for the detection of bacteria of the genus Campylobacter
KR1020207011395A KR102653734B1 (ko) 2017-10-02 2018-10-02 캄필로박터 속 박테리아를 검출하기 위한 항체 및 검사 디바이스

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382654.6A EP3461841B1 (fr) 2017-10-02 2017-10-02 Anticorps contre dps et dispositifs d'essai pour la détection de bactéries du genre campylobacter

Publications (2)

Publication Number Publication Date
EP3461841A1 true EP3461841A1 (fr) 2019-04-03
EP3461841B1 EP3461841B1 (fr) 2019-09-11

Family

ID=60164631

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17382654.6A Active EP3461841B1 (fr) 2017-10-02 2017-10-02 Anticorps contre dps et dispositifs d'essai pour la détection de bactéries du genre campylobacter

Country Status (7)

Country Link
US (1) US11312762B2 (fr)
EP (1) EP3461841B1 (fr)
JP (1) JP7212682B2 (fr)
KR (1) KR102653734B1 (fr)
CN (1) CN111727200B (fr)
ES (1) ES2759622T3 (fr)
WO (1) WO2019068733A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023067793A (ja) * 2021-10-29 2023-05-16 花王株式会社 新規ラテラルフローアッセイ

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125023A1 (fr) 1983-04-08 1984-11-14 Genentech, Inc. Préparations d'immunoglobuline recombinante, méthodes pour leur préparation, séquences d'ADN, vecteurs d'expression et cellules d'hôtes recombinantes
EP0171496A2 (fr) 1984-08-15 1986-02-19 Research Development Corporation of Japan Procédé pour la production d'un anticorps monoclonal chimérique
EP0173494A2 (fr) 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
WO1986001533A1 (fr) 1984-09-03 1986-03-13 Celltech Limited Production d'anticorps chimeriques
EP0184187A2 (fr) 1984-12-04 1986-06-11 Teijin Limited Chaîne lourde d'immunoglobuline chimère souris-humaine et chimère de l'ADN codant celle-ci
GB2188638A (en) 1986-03-27 1987-10-07 Gregory Paul Winter Chimeric antibodies
WO1990002809A1 (fr) 1988-09-02 1990-03-22 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
EP0388151A1 (fr) 1989-03-13 1990-09-19 Celltech Limited Anticorps modifiés
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
WO1991017271A1 (fr) 1990-05-01 1991-11-14 Affymax Technologies N.V. Procedes de triage de banques d'adn recombine
WO1992001047A1 (fr) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Procede de production de chainon de paires a liaison specifique
WO1992003918A1 (fr) 1990-08-29 1992-03-19 Genpharm International, Inc. Animaux non humains transgeniques capables de produire des anticorps heterologues
WO1992003917A1 (fr) 1990-08-29 1992-03-19 Genpharm International Recombinaison homologue dans des cellules de mammiferes
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
WO1992015679A1 (fr) 1991-03-01 1992-09-17 Protein Engineering Corporation Phage de visualisation d'un determinant antigenique ameliore
WO1992018619A1 (fr) 1991-04-10 1992-10-29 The Scripps Research Institute Banques de recepteurs heterodimeres utilisant des phagemides
WO1992020791A1 (fr) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
EP0519596A1 (fr) 1991-05-17 1992-12-23 Merck & Co. Inc. Procédé pour réduire l'immunogénécité des domaines variables d'anticorps
WO1993001288A1 (fr) 1991-07-08 1993-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemide utile pour trier des anticorps
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1994004678A1 (fr) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulines exemptes de chaines legeres
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US6569635B1 (en) * 1998-05-18 2003-05-27 Board Of Regents Of The University Of Nebraska Growth state-specific immunofluorescent probes for determining physiological state and method of use
WO2008008092A2 (fr) * 2006-07-10 2008-01-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Protéine de pilus campylobacter, compositions et procédés
JP2009077658A (ja) 2007-09-26 2009-04-16 Osaka Prefecture 便中のカンピロバクターの迅速検出方法
US8602269B2 (en) 2009-09-14 2013-12-10 Guala Dispensing S.P.A. Trigger sprayer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091261A1 (es) 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
US20110076723A1 (en) 2008-05-23 2011-03-31 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
MX2016007958A (es) 2013-12-17 2016-08-03 Genentech Inc Anticuerpos anti-cd3 y metodos de uso.
CN106810609A (zh) 2015-11-27 2017-06-09 苏州君盟生物医药科技有限公司 抗pcsk9抗体及其应用

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0125023A1 (fr) 1983-04-08 1984-11-14 Genentech, Inc. Préparations d'immunoglobuline recombinante, méthodes pour leur préparation, séquences d'ADN, vecteurs d'expression et cellules d'hôtes recombinantes
EP0171496A2 (fr) 1984-08-15 1986-02-19 Research Development Corporation of Japan Procédé pour la production d'un anticorps monoclonal chimérique
EP0173494A2 (fr) 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
WO1986001533A1 (fr) 1984-09-03 1986-03-13 Celltech Limited Production d'anticorps chimeriques
EP0184187A2 (fr) 1984-12-04 1986-06-11 Teijin Limited Chaîne lourde d'immunoglobuline chimère souris-humaine et chimère de l'ADN codant celle-ci
GB2188638A (en) 1986-03-27 1987-10-07 Gregory Paul Winter Chimeric antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
WO1990002809A1 (fr) 1988-09-02 1990-03-22 Protein Engineering Corporation Production et selection de proteines de liaison diversifiees de recombinaison
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
EP0388151A1 (fr) 1989-03-13 1990-09-19 Celltech Limited Anticorps modifiés
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
WO1991017271A1 (fr) 1990-05-01 1991-11-14 Affymax Technologies N.V. Procedes de triage de banques d'adn recombine
WO1992001047A1 (fr) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Procede de production de chainon de paires a liaison specifique
WO1992020791A1 (fr) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methode de production de chainons de paires de liaison specifique
WO1992003918A1 (fr) 1990-08-29 1992-03-19 Genpharm International, Inc. Animaux non humains transgeniques capables de produire des anticorps heterologues
WO1992003917A1 (fr) 1990-08-29 1992-03-19 Genpharm International Recombinaison homologue dans des cellules de mammiferes
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
WO1992015679A1 (fr) 1991-03-01 1992-09-17 Protein Engineering Corporation Phage de visualisation d'un determinant antigenique ameliore
WO1992018619A1 (fr) 1991-04-10 1992-10-29 The Scripps Research Institute Banques de recepteurs heterodimeres utilisant des phagemides
EP0519596A1 (fr) 1991-05-17 1992-12-23 Merck & Co. Inc. Procédé pour réduire l'immunogénécité des domaines variables d'anticorps
WO1993001288A1 (fr) 1991-07-08 1993-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Phagemide utile pour trier des anticorps
WO1994004678A1 (fr) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulines exemptes de chaines legeres
US6569635B1 (en) * 1998-05-18 2003-05-27 Board Of Regents Of The University Of Nebraska Growth state-specific immunofluorescent probes for determining physiological state and method of use
WO2008008092A2 (fr) * 2006-07-10 2008-01-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Protéine de pilus campylobacter, compositions et procédés
JP2009077658A (ja) 2007-09-26 2009-04-16 Osaka Prefecture 便中のカンピロバクターの迅速検出方法
JP5467228B2 (ja) 2007-09-26 2014-04-09 大阪府 便中のカンピロバクターの迅速検出方法
US8602269B2 (en) 2009-09-14 2013-12-10 Guala Dispensing S.P.A. Trigger sprayer

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
"Affinity Chromatography Vol. 1: Antibodies handbook 18103746 AF", vol. 1, April 2016, GE HEALTHCARE BIO-SCIENCES AB
AI-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982
BEIDLER ET AL., J. IMMUNOL., vol. 141, 1988, pages 4053 - 4060
BESSEDE ET AL.: "New Methods for Detection of Campylobacters in Stool samples in comparation to culture", J.CLIN. MICROB., 2011, pages 941 - 944
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BRUGGEMAN ET AL., EUR J IMMUNOL, vol. 21, 1991, pages 1323 - 1326
BRUGGEMAN ET AL., YEAR IMMUNOL, vol. 7, 1993, pages 33 - 40
CHOTHIA, C. ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
COLCHER, D. ET AL., ANN N Y ACAD SCI, vol. 880, 1999, pages 263 - 80
COUTURIER ET AL.: "Detection of non -jejuni and ampylobacter species from stool specimens with an immunochromatographic antigen detection assay", J. CLIN MICROBIOL., vol. 6, 2003, pages 1935 - 7
DUEBEL, S. AND KONTERMANN, R.: "Antibody Engineering Lab Manual", SPRINGER-VERLAG, article "Protein Sequence and Structure Analysis of Antibody Variable Domains"
FUCHS ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1370 - 1372
GARRAD ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1373 - 1377
GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580
GRANATO ET AL.: "Comparison of Premier CAMPY Enzyme Immnunoassay (EIA), ProSpecT Campylobacter EIA, and Immuno Card STAT! CAMPY test with culture for laboratory diagnosis of ampylobacter enteric infections", J.CLIN. MICROB., 2010, pages 4022 - 4027
GREEN, L.L. ET AL., NATURE GENET., vol. 7, 1994, pages 13 - 21
GRIFFTHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734
HAWKINS ET AL., J MOL BIOL, vol. 226, 1992, pages 889 - 896
HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85
HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137
HUA PIAO ET AL: "Tissue Binding Patterns and In Vitro Effects of DNA-Binding Protein from Starved Cells", NEUROCHEMICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 36, no. 1, 19 September 2010 (2010-09-19), pages 58 - 66, XP019855330, ISSN: 1573-6903, DOI: 10.1007/S11064-010-0263-7 *
HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
ISHIKAWA ET AL., J. BACTERIOL., vol. 185, no. 3, 2003, pages 1010 - 1017
ISHIKAWA T ET AL: "The iron-binding protein Dps confers hydrogen peroxide stress resistance to Campylobacter jejuni", JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 185, no. 3, 1 February 2003 (2003-02-01), pages 1010 - 1017, XP002554975, ISSN: 0021-9193, DOI: 10.1128/JB.185.3.1010-1017.2003 *
JONES ET AL., NATURE, vol. 321, 1986, pages 552 - 525
KABAT ET AL.: "Sequences of Proteins of Immunological Interest, 5th ed.", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KABAT, E. A. ET AL.: "Sequences of Proteins of Immunological Interest, 5th ed.", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH PUBLICATION
KOHLER G; MILSTEIN C: "Continuous cultures of fused cells secreting antibody of predefined specificity", NATURE, vol. 256, no. 5517, 7 August 1975 (1975-08-07), pages 495 - 497, XP002024548
LIU ET AL., J. IMMUNOL., vol. 139, 1987, pages 3521 - 3526
LIU ET AL., PNAS, vol. 84, 1987, pages 3439 - 3443
LONBERG, N. ET AL., NATURE, vol. 368, 1994, pages 856 - 859
MORRISON, S. L., SCIENCE, vol. 229, 1985, pages 1202 - 1207
MORRISON, S.L. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1994, pages 6851 - 6855
NISHIMURA ET AL., CANC. RES., vol. 47, 1987, pages 999 - 1005
OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214
REITER, Y., CLIN CANCER RES, vol. 2, 1996, pages 245 - 52
SHAW ET AL., J. NATL CANCER INST., vol. 80, 1988, pages 1553 - 1559
SUN ET AL., PNAS, vol. 84, 1987, pages 214 - 218
TUAILLON ET AL., PNAS, vol. 90, 1993, pages 3720 - 3724
VERHOEYAN ET AL., SCIENCE, vol. 239, 1988, pages 1534
WINNAKER: "From Genes to Clones", 1987, VERLAGSGESELLSCHAFT
WOOD ET AL., NATURE, vol. 314, 1985, pages 446 - 449

Also Published As

Publication number Publication date
ES2759622T3 (es) 2020-05-11
JP7212682B2 (ja) 2023-01-25
US20200317756A1 (en) 2020-10-08
CN111727200A (zh) 2020-09-29
KR102653734B1 (ko) 2024-04-01
KR20200059257A (ko) 2020-05-28
JP2020536117A (ja) 2020-12-10
CN111727200B (zh) 2022-11-01
US11312762B2 (en) 2022-04-26
EP3461841B1 (fr) 2019-09-11
WO2019068733A1 (fr) 2019-04-11

Similar Documents

Publication Publication Date Title
CN105579471A (zh) 结合人程序性死亡配体1(pd-l1)的抗体
US11372001B2 (en) Anti-human IgG4 monoclonal antibody and methods of making and using same
CN111518202B (zh) 新型冠状病毒抗体和新型冠状病毒抗体的elisa检测试剂盒
JP2011510291A (ja) 治療用抗体に対する抗体を検出する方法およびキット
CN105531290A (zh) 获取april结合肽的方法，产生该肽的过程，用所述方法/过程获取的april结合肽以及该肽的用途
US11312762B2 (en) Antibodies and test devices for the detection of bacteria of the genus Campylobacter
CN112898416B (zh) 新型冠状病毒np蛋白的结合蛋白及其应用
CN112979794B (zh) 检测新型冠状病毒抗原的产品及其包含的抗体
MX2013002870A (es) Ensayo de deteccion residual de anticuerpo monoclonal altamente sensible.
CN105504062A (zh) 一种抗CD6单抗T1h的检测性抗体及应用
AP156A (en) Agglutination assay.
TWI741216B (zh) 專一性抑制或減緩ｐｔｘ３與ｐｔｘ３受體結合之單株抗體或其抗原結合片段及其用途
US7563875B2 (en) Recombinant chimeric human anti-botulinum antibodies
KR20180020992A (ko) 피검 대상의 검출 방법 및 그것을 위한 면역 측정 기구 및 모노클로널 항체
KR102601835B1 (ko) 말 인플루엔자 바이러스 h3n8형에 특이적인 단일클론항체 및 이를 이용한 말인플루엔자 바이러스 검출용 조성물
CN115677851B (zh) 一种免疫阻断抗体或其抗原结合片段及其应用
CN112979793B (zh) 检测新型冠状病毒的抗体
KR102661060B1 (ko) 항인간 IgG4 모노클로날 항체, 및 그 항체를 이용한 인간 IgG4 측정 시약
US20150355170A1 (en) Compositions, systems and methods that detect and/or remove cross-reactive antibodies from a biological sample
AU633633B2 (en) Agglutination assay
US20230257460A1 (en) Compounds and methods targeting human and mouse insl5
CN112094345A (zh) 可应用于肿瘤细胞捕获的小鼠抗免疫球蛋白关联βCD79b的单克隆抗体
CN116143931A (zh) 一种抗人IgM抗体及其制备方法和用途
Rönnmark Affibody ligands in immunotechnology applications

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180725

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190606

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1178340

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190915

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017006986

Country of ref document: DE

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190911

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191212

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1178340

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200113

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2759622

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017006986

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG2D Information on lapse in contracting state deleted

Ref country code: IS

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191002

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200112

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191031

26N No opposition filed

Effective date: 20200615

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201031

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20171002

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231026

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231102

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231023

Year of fee payment: 7

Ref country code: FR

Payment date: 20231018

Year of fee payment: 7

Ref country code: FI

Payment date: 20231004

Year of fee payment: 7

Ref country code: DE

Payment date: 20231018

Year of fee payment: 7